BENznidazole Evaluation for Interrupting Trypanosomiasis Trial
To determine if 60 days of treatment with an antiparasitic drug (benznidazole) could prevent the progression of cardiac disease in patients with Chagas disease. The BENEFIT study is being conducted by the Population Health Research Institute (in Hamilton, Canada) and the Institute Dante Pazzanese de Cardiologia (Sao Paulo, Brazil) together with an independent Steering Committee.
Randomized, double-blind, placebo control, safety/efficacy study, single group assignment, treatment.
Adjudicated. Cardiac Arrest or other thromboembolic event in patients w/no prior thromboembolic phenomena or death Secondary Endpoint: New development of the following echo changes; segmental wall motion abnormalities, ventricular aneurysm, reduction in LV ejection fraction > 5%, increase in LVDD > 5.0 mm compared with baseline. New 12 lead ECG alterations (complete bundle branch block, fascicular block, advanced atrio-ventricular block, atrial fibrillation, etc). Progression of NYHA functional class by at least one category.
Susan Chrolavicius, Brandi Meeks
Marin-Neto, JA, Raasi Jr., A, Morillo, CA, Avezum, A, Connolly, SJ, Sosa-Estani, S, Rosas, F, Yusuf, S for the BENEFIT Investigators. Rational and design of a randomized placebo-controlled assessing the effects of etiologic treatment in Chagas’ cardiomyopathy: The BENznidazole Evaluation For Interrupting Trypanosmiasis (BENEFIT). AM Heart J; 2008; 156(1): 37-43.
Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A Jr, Rosas F, Villena E, Quiroz R, Bonilla R, Britto C, Guhl F, Velazquez E, Bonilla L, Meeks B, Rao-Melacini P, Pogue J, Mattos A, Lazdins J, Rassi A, Connolly SJ, Yusuf S; BENEFIT Investigators. Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy. N Engl J Med 2015; 373(14): 1295-306.